Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Geoffrey Z L Kuppens; Maria Armila D Ruiz; Myrthe J Van Dijk; Minke A E Rab; Cleo Derichs; Joline Saes; Anita W Rijneveld; Marjon H Cnossen; Erfan Nur; Bart J Biemond; Marije Bartels; Santosh L Saraf; Eduard J Van Beers

doi:10.3324/haematol.2025.289105

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Geoffrey Z L Kuppens
, Maria Armila D Ruiz
, Myrthe J Van Dijk
, Minke A E Rab
, Cleo Derichs
, Joline Saes
, Anita W Rijneveld
, Marjon H Cnossen
, Erfan Nur
, Bart J Biemond
, Marije Bartels
, Santosh L Saraf
, Eduard J Van Beers^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2792-2796
Number of pages	5
Journal	Haematologica
Volume	111
Issue number	8
Early online date	26 Feb 2026
DOIs	https://doi.org/10.3324/haematol.2025.289105
Publication status	Published - Aug 2026

Access to Document

10.3324/haematol.2025.289105Licence: CC BY

13179-Article Text-90415-2-10-20260708Final published version, 196 KBLicence: CC BY

Cite this

Kuppens, G. Z. L., Ruiz, M. A. D., Van Dijk, M. J., Rab, M. A. E., Derichs, C., Saes, J., Rijneveld, A. W., Cnossen, M. H., Nur, E., Biemond, B. J., Bartels, M., Saraf, S. L., & Van Beers, E. J. (2026). Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study. Haematologica, 111(8), 2792-2796. https://doi.org/10.3324/haematol.2025.289105

@article{1f59326b486e4388ac37c9571d491733,

title = "Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study",

author = "Kuppens, \{Geoffrey Z L\} and Ruiz, \{Maria Armila D\} and \{Van Dijk\}, \{Myrthe J\} and Rab, \{Minke A E\} and Cleo Derichs and Joline Saes and Rijneveld, \{Anita W\} and Cnossen, \{Marjon H\} and Erfan Nur and Biemond, \{Bart J\} and Marije Bartels and Saraf, \{Santosh L\} and \{Van Beers\}, \{Eduard J\}",

year = "2026",

month = aug,

doi = "10.3324/haematol.2025.289105",

language = "English",

volume = "111",

pages = "2792--2796",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "8",

}

Kuppens, GZL, Ruiz, MAD, Van Dijk, MJ , Rab, MAE, Derichs, C, Saes, J, Rijneveld, AW, Cnossen, MH, Nur, E, Biemond, BJ, Bartels, M, Saraf, SL & Van Beers, EJ 2026, 'Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study', Haematologica, vol. 111, no. 8, pp. 2792-2796. https://doi.org/10.3324/haematol.2025.289105

TY - JOUR

T1 - Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease

T2 - results from the phase 2 open-label study

AU - Kuppens, Geoffrey Z L

AU - Ruiz, Maria Armila D

AU - Van Dijk, Myrthe J

AU - Rab, Minke A E

AU - Derichs, Cleo

AU - Saes, Joline

AU - Rijneveld, Anita W

AU - Cnossen, Marjon H

AU - Nur, Erfan

AU - Biemond, Bart J

AU - Bartels, Marije

AU - Saraf, Santosh L

AU - Van Beers, Eduard J

PY - 2026/8

Y1 - 2026/8

U2 - 10.3324/haematol.2025.289105

DO - 10.3324/haematol.2025.289105

M3 - Article

C2 - 41742872

SN - 0390-6078

VL - 111

SP - 2792

EP - 2796

JO - Haematologica

JF - Haematologica

IS - 8

ER -

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Access to Document

Fingerprint

Cite this